Mutual of America Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Mutual of America Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-5,500	Closed	-$45K	–	1695
2019 Q1	$45K	Sell	5,500 -129,033	-96%	-$885K	﹤0.01%	1309
2018 Q4	$744K	Hold	134,533	–	–	0.01%	1088
2018 Q3	$1.19M	Buy	134,533 +604	+0.5%	+$5.4K	0.02%	1062
2018 Q2	$1.34M	Hold	133,929	–	–	0.02%	1040
2018 Q1	$1.28M	Buy	133,929 +3,750	+3%	+$52.5K	0.02%	1028
2017 Q4	$1.94M	Buy	130,179 +18,779	+17%	+$311K	0.03%	887
2017 Q3	$2.19M	Buy	+111,400	New	+$1.71M	0.04%	795

Other funds holding AKBA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mutual of America Capital Management's AKBA Position: Q2 2019 in Review

Mutual of America Capital Management sold out of Akebia Therapeutics (AKBA) in Q2 2019, closing a stake of 5,500 shares — an estimated $45K sold.

Mutual of America Capital Management first reported a position in AKBA in Q3 2017 and held it in 7 quarters. The position peaked at $2.19M in Q3 2017. 151 funds tracked by Wall St. Rank hold AKBA as of Q2 2019.

Mutual of America Capital Management reported no remaining Akebia Therapeutics position as of Q2 2019 after selling out during the quarter.
Mutual of America Capital Management sold 5,500 Akebia Therapeutics shares in Q2 2019, an estimated $45K.
Mutual of America Capital Management first reported a position in Akebia Therapeutics in Q3 2017 and held it in 7 quarters.
Mutual of America Capital Management's Akebia Therapeutics position peaked at $2.19M in Q3 2017.
151 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2019.

Based on Mutual of America Capital Management's 13F filing for Q2 2019, filed 12 Aug 2019.